| Title |
Long-term therapeutic effects and safety of tacrolimus added to methotrexate in patients with rheumatoid arthritis
|
|---|---|
| Published in |
Rheumatology International, July 2012
|
| DOI | 10.1007/s00296-012-2465-6 |
| Pubmed ID | |
| Authors |
Takeyuki Kanzaki, Kimito Kawahata, Hiroko Kanda, Keishi Fujio, Kanae Kubo, Lisa Akahira, Kazuya Michishita, Toshiki Eri, Kazuhiko Yamamoto |
| Abstract |
To assess the long-term safety and efficacy of tacrolimus (TAC) used in combination with oral methotrexate (MTX) in patients with rheumatoid arthritis (RA) whose disease remains active despite treatment with MTX alone. The clinical courses of 24 RA patients who received TAC added to MTX from a single center were analyzed retrospectively. The disease activity was evaluated by the DAS28-ESR(3) every 12 months after the addition of TAC, and side effects were evaluated for 3 years. At 3 years after starting the treatment, TAC was still being used by 19 patients (79 %). The causes of discontinuation were an inadequate response (3 cases), oral ulcers and elevation of creatinine (1 case), and worsening of interstitial pneumonia (1 case). No death was registered. The DAS28-ESR(3) was decreased from 4.81 to 3.41 after 3 years of treatment. The doses of prednisolone were decreased from 5.1 mg/day to 3.2 mg/day after 3 years. In patients whose active RA persists despite treatment with MTX, TAC in combination with MTX is safe and well tolerated and provided clinical benefit for a long time in this single-center retrospective study. Further studies are required to confirm the safety and efficacy of this combination therapy. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 18 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 18 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 3 | 17% |
| Student > Ph. D. Student | 3 | 17% |
| Student > Doctoral Student | 2 | 11% |
| Student > Master | 2 | 11% |
| Professor | 2 | 11% |
| Other | 3 | 17% |
| Unknown | 3 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 56% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 11% |
| Immunology and Microbiology | 1 | 6% |
| Nursing and Health Professions | 1 | 6% |
| Unknown | 4 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 October 2013.
All research outputs
#15,284,663
of 22,729,647 outputs
Outputs from Rheumatology International
#1,531
of 2,174 outputs
Outputs of similar age
#104,149
of 163,937 outputs
Outputs of similar age from Rheumatology International
#9
of 17 outputs
Altmetric has tracked 22,729,647 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,174 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.6. This one is in the 22nd percentile – i.e., 22% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 163,937 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.